1 not yet recruiting, 1 recruiting. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Not yet recruiting 1, Recruiting 1 |
Follow Non-vestibular Schwannoma: new trials by email Literature Review of Non-vestibular Schwannoma trials Research Report on Non-vestibular Schwannoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2) Selumetinib 25mg/m2, Luvometinib, Serplulimab - Neurofibromatosis Type 2, Vestibular Schwannoma | Phase 2 | Not yet recruiting | Beijing Tiantan Hospital | 200 | 2026-07-18 | 2026-07-20 |
| Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2) Brigatinib, Neratinib, Retifanlimab - Neurofibromatosis Type 2, Vestibular Schwannoma | Phase 2 | Recruiting | Scott R. Plotkin, MD, PhD | 109 | 2020-06-20 | 2026-10-28 |
Ependymoma (2) · Meningioma (2) · Neurofibromatosis 2 (2) · Neuroma, Acoustic (2)
Central Nervous System Neoplasms (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Cranial Nerve Diseases (2) · Cranial Nerve Neoplasms (2) · Ear Diseases (2) · Genetic Diseases, Inborn (2) · Glioma (2) · Heredodegenerative Disorders, Nervous System (2) · Meningeal Neoplasms (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Neoplasms, Germ Cell and Embryonal (2) · Neoplasms, Glandular and Epithelial (2) · Neoplasms, Nerve Tissue (2)
AZD 6244 (1) · Bevacizumab (1) · brigatinib (1) · neratinib (1)
Beijing Tiantan Hospital (1) · Scott R. Plotkin, MD, PhD (1)
China (1) · United States (1)